Article By:
KKD Healthcare Analytics
Monday, April 24, 2017 10:03 AM EDT
Johnson & Johnson announced results from a Phase 2 clinical trial assessing the triple combination ofOlysio (simeprevir), C.R. Bard Inc. and Becton Dickinson finalize the deal for buying Bard.